Drug discovery is where pharmaceutical and biotech companies either build long-term value or bleed it quietly over years. As CEO, your relationship with the discovery portfolio is one of the most consequential time allocation decisions you make, and it is also one of the most mismanaged. Too much involvement turns you into a shadow CSO; too little and the portfolio drifts away from strategic intent without anyone noticing until it is far too late to course-correct cheaply.
This article is for CEOs who want to structure their discovery oversight with intention: knowing which decisions genuinely require your input, how to calibrate time against stage, and how to build the kind of CSO relationship that keeps early-stage science healthy without pulling you out of your highest-leverage work.
Why Discovery Portfolio Oversight Is a CEO Problem
The standard CEO playbook on R&D tends to over-index on late-stage pipeline, where the capital at risk is highest and board visibility is greatest. That instinct is understandable. A Phase 3 readout can move the stock price by 30% overnight, so the gravitational pull toward late-stage attention is real.
But the strategic shape of your company five to ten years from now is being determined right now, in discovery. Which biology you are betting on, which modalities you are building capability in, which indications you are entering or exiting: these choices compound over time in ways that late-stage decisions simply cannot undo. A CEO who checks in on discovery only when programs reach IND filing is, in effect, ratifying a science strategy they never actually reviewed.
The challenge is that discovery timelines are long, the uncertainty is high, and the scientific complexity is genuine. You are not the expert in the room. The question is not whether you can out-science your CSO. The question is whether you are spending enough time to ensure that discovery priorities reflect company strategy, not just scientific preference.
Which Discovery Decisions Actually Need You
Not every program review, target validation debate, or platform investment discussion requires CEO involvement. Part of effective discovery governance is knowing where to draw the line, because drawing it too broadly exhausts your credibility and your calendar.
Strategic Target Selection
When your research organization is choosing which biological targets to advance into formal programs, that decision has strategy embedded in it. Target selection is never purely scientific; it reflects assumptions about competitive landscape, patient population size, regulatory feasibility, and the kind of company you want to be in ten years. A CSO making target selection decisions in isolation is, whether they intend to or not, making those strategic calls on your behalf.
Your job here is not to second-guess the biology. It is to ensure that the strategic assumptions underneath the scientific choices have been surfaced and evaluated at the right level. A 90-minute annual review of the target selection framework, combined with a standing expectation that major new target entries come to you with a one-page strategic rationale, is usually sufficient to keep this honest.
Modality and Platform Bets
Decisions about which drug modalities to invest in, whether small molecules, biologics, RNA therapeutics, cell therapies, or anything else, are capital allocation decisions that carry a decade of consequence. They require manufacturing capability, talent strategy, partnership positioning, and intellectual property posture that cannot be unwound cheaply. These belong on your agenda in a way that routine program updates do not.
You should be the owner of the question: are we building internal capability, or are we accessing this modality through partnerships and acquisitions? That question sits at the intersection of science, finance, and business development in a way that only the CEO can resolve with authority.
Portfolio Balance and Investment Allocation
Early-stage research budgets are often allocated bottom-up, based on what scientists want to work on and what proposals have been submitted. The result, left unmanaged, is a portfolio that reflects scientific interest more than strategic intent. You need a top-down view on portfolio balance: how much early-stage investment is going into each therapeutic area, each modality, each risk tier.
This does not mean micromanaging individual program budgets. It means setting the parameters within which the CSO and research leadership operate, and reviewing the aggregate picture at least twice a year. For guidance on integrating this with broader pipeline governance, see pipeline governance decisions.
Program Termination
Killing programs is one of the hardest things a research organization does, and it is one of the places where CEO involvement has the highest leverage. Scientists are, rationally, optimistic about the programs they are running. Termination decisions face organizational resistance even when the science is clearly not working. A CSO who has to make a termination call without CEO backing is in a difficult position, and the result is often programs that survive well past the point where the capital could have been redeployed more productively.
You do not need to be in every program review that might lead to termination. But you should be explicit with your CSO that you want visibility on major program terminations before they are finalized, and that you will back them up when the call is right. That backing is itself a form of time investment, even if it only takes an hour.
Structuring the CSO Relationship
The CSO relationship is the central lever for effective discovery oversight. If you get this right, you can maintain meaningful governance without spending time you do not have on science you cannot fully evaluate.
What the CSO Needs From You
Your CSO needs three things to function well: clarity on strategic priorities, protection from short-term financial pressure that would distort research decisions, and a CEO who engages substantively enough to be a credible counterpart.
That last point is worth dwelling on. A CSO who perceives their CEO as scientifically disengaged will, over time, stop bringing the hard questions to the CEO and start resolving them internally. The result is a research organization that becomes progressively less accountable to strategic intent. You do not need to become a scientist. You need to demonstrate enough engagement that your CSO knows the conversation will be worth having.
Cadence and Format
A monthly one-on-one with your CSO, focused specifically on discovery rather than clinical or regulatory topics, is the foundation. This should not be a status report. It should be a genuine conversation about where the science is creating strategic opportunities or problems, where the CSO has decisions pending that need your input, and where you see misalignment between research direction and company strategy.
Quarterly, you should see a portfolio-level view: how programs are distributed across therapeutic areas and modalities, where the portfolio is concentrated or thin, and what the investment trend lines look like over the next 12 to 18 months. This can be a two-hour working session rather than a polished presentation.
Annually, you and your CSO should conduct a more comprehensive strategy review: are the platform bets you made two to three years ago playing out? Are there modality capabilities you should be building or exiting? Is the discovery portfolio aligned with where you expect the commercial and regulatory environment to be in ten years?
When the CSO and CEO Disagree
Disagreements between CEO and CSO on discovery strategy are healthy and should be expected. The question is how you resolve them. The worst outcome is a protracted standoff where neither party is willing to make a decision, and programs drift in strategic limbo. The second worst outcome is a CEO who overrides the CSO’s scientific judgment on a question where the CSO has the relevant expertise.
The right frame is a division of authority: the CSO has final say on scientific questions, including whether the biology is compelling enough to advance a program. The CEO has final say on strategic questions, including whether the indication fits the company’s long-term positioning, whether the competitive dynamics justify the investment, and whether the risk profile of the portfolio is appropriate. When these domains overlap, the resolution requires genuine dialogue, not hierarchy.
Balancing Discovery Against the Rest of Your R&D Agenda
Discovery is one layer of an R&D agenda that also includes clinical development, regulatory strategy, and medical affairs. CEOs who have not explicitly allocated time across these layers tend to find their R&D attention dominated by whatever is most urgent, which is almost always late-stage clinical.
A useful heuristic: if your company has a credible early-stage pipeline, you should be spending at least 20 to 25 percent of your total R&D-related time on discovery and early development. For companies that are primarily in the research phase, that number should be higher. For companies that are primarily commercial with a thin pipeline, it may need to be even higher, because rebuilding discovery capability is one of the hardest turnaround challenges a pharma CEO faces.
The other time allocation question is how to split your attention across research governance, early development decisions, and the transition from discovery to development. The IND-enabling period, where a program moves from discovery science to formal development candidate status, is a point of particular CEO leverage. Programs that enter development without adequate strategic review tend to consume resources for years before the fundamental strategic misfit becomes visible.
Common Discovery Oversight Failures
Several patterns recur in pharma and biotech CEOs who are not getting adequate value from their discovery oversight time.
Over-reliance on board-level portfolio updates. Board presentations are summaries, not working sessions. If your primary source of discovery portfolio information is what gets presented to the board, you are getting a curated view that has already passed through multiple layers of organizational optimism.
Treating discovery purely as an expense line. When discovery is managed primarily as a cost center, the governance model focuses on budget compliance rather than strategic output. The right measure of discovery investment is not whether you are hitting your R&D expense target; it is whether the portfolio is generating the options your company needs for its next strategic phase.
Delegating science strategy to business development. Business development teams are often better resourced than internal research, and CEOs sometimes find it easier to shape the portfolio through acquisitions and partnerships than through direct engagement with internal research governance. This is not wrong as a strategy, but it creates organizational drift when internal research teams lose confidence that their work is valued and strategically connected.
Allowing target concentration to build silently. It is common for discovery portfolios to become quietly concentrated in a single pathway, mechanism class, or therapeutic area over time, not through deliberate choice but through the accumulation of individual program decisions that each made local sense. A CEO who is not looking at the aggregate picture regularly will not see this concentration until it becomes a strategic vulnerability.
Allocating Your Discovery Time: A Practical Structure
Based on the governance requirements above, here is a concrete time allocation framework for a pharma or biotech CEO with a meaningful internal discovery organization.
Monthly commitment: a 60 to 90-minute one-on-one with the CSO, plus availability for escalated decisions that the CSO flags as requiring CEO input. Budget roughly four to six hours per month in a steady state, more when major portfolio decisions are pending.
Quarterly commitment: a half-day portfolio review covering discovery-stage programs, platform investments, and the early-to-development pipeline transition. This is a working session, not a presentation.
Annual commitment: a full-day discovery strategy review with the CSO and senior research leadership. This is where you review platform bets, therapeutic area positioning, and the alignment between discovery priorities and the company’s five-year strategic intent. This review should be on the calendar before the year begins.
Ad hoc: termination decisions that the CSO escalates, major new target or modality investments, and competitive intelligence that suggests a strategic recalibration in early-stage priorities.
Total annual time investment for a company with a meaningful discovery organization: roughly 60 to 80 hours. That is roughly 3 to 4 percent of a CEO’s annual working time. Given that discovery determines the long-term strategic shape of the company, that is a proportionate investment, not an excessive one.
The Compounding Value of Consistent Engagement
The most important thing about discovery oversight is not any single decision. It is the organizational signal that consistent CEO engagement sends. When research teams know that the CEO has a genuine understanding of the portfolio, makes time for discovery governance, and is willing to have hard conversations about program termination and strategic misalignment, the quality of the decisions that come up to you improves. Scientists surface problems earlier. CSOs are more willing to kill programs that are not working. Strategic drift gets corrected before it becomes expensive.
That compounding organizational effect is why the time investment in discovery governance is worth more than the sum of the individual decisions it produces. The CEO who is genuinely engaged with early-stage science is building a research culture that makes better decisions at every level, not just the ones that reach the executive committee.
Discovery is where pharmaceutical companies create the options that sustain them. How you allocate time to it is how you exercise your most consequential form of strategic stewardship.